Wednesday, October 22, 2014 Last update: 9:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Mallinckrodt Pharmaceuticals to Hold Investor Briefing October 14, 2014, in New York

Companies mentioned in this article: Mallinckrodt

DUBLIN -- (BUSINESS WIRE) -- Mallinckrodt plc. (NYSE: MNK), a leading global specialty pharmaceutical company, will hold an investor briefing on Tuesday, October 14, 2014, in New York City. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will present along with members of Mallinckrodt’s senior management team. The presentation will include announcement of the company’s fiscal year 2015 financial guidance.

The briefing will take place from 9 a.m. to 11 a.m. Eastern Time at The Plaza, 770 Fifth Ave., New York, NY 10019. Those interested in attending should register by contacting investor.relations@mallinckrodt.com.

Individuals unable to attend the briefing in person can view a live webcast at Mallinckrodt’s Investor Relations website: http://www.mallinckrodt.com/investor_relations/. The briefing is also available live via conference call at 1-844-867-9755 in the United States and 901-300-3301 outside the United States; all callers should use the access code 95905912.

The presentation replay and materials will be available for a seven-day period on the Mallinckrodt Investor Relations website following the end of the event.

ABOUT MALLINCKRODT:

Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.


Copyright © Business Wire 2014
Contact:

Mallinckrodt
Rhonda Sciarra, 314-654-8618
Manager, Communications
rhonda.sciarra@mallinckrodt.com
or
Meredith Fischer, 314-654-3318
Senior Vice President, Communications
meredith.fischer@mallinckrodt.com
or
John Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com